‘Sweet spot’ of CNS cell therapy: Kenai emerges with $82M for Parkinson’s study

One of the first drugs that Jeff Jonas filed for approval was a Parkinson’s disease treatment. Now, a little over a quarter century later, after executive roles at Shire and Sage Therapeutics, he’s chairing a young startup with $82 million to test whether an off-the-shelf cell…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks